Cargando…

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study

BACKGROUND AND AIM: Infliximab is typically given over an infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared with the standard 2-hour...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abushamma, Suha, Walker, Ted, Garza, Kevin, Chen, Ling, Nix, Darren, Chen, Chien-Huan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243871/ https://www.ncbi.nlm.nih.gov/pubmed/37288326 http://dx.doi.org/10.1093/crocol/otad022

Ejemplares similares

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
por: Viola, Anna, et al.
Publicado: (2017)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
por: Ong, Wan Chee, et al.
Publicado: (2022)

Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives
por: Kochar, Bharati, et al.
Publicado: (2021)

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2023)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center
por: Park, Jiyeon Joy, et al.
Publicado: (2018)

Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions
por: Kelly, Maureen M., et al.
Publicado: (2019)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Influence of capsaicin infusion on secondary peristalsis in patients with gastroesophageal reflux disease
por: Yi, Chih-Hsun, et al.
Publicado: (2016)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam
por: Koumaki, Vasiliki, et al.
Publicado: (2023)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

Predictors of infusion reactions during infliximab treatment in patients with arthritis
por: Kapetanovic, Meliha C, et al.
Publicado: (2006)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting
por: Checkley, L. Allyson, et al.
Publicado: (2018)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study
por: Wang, Xiaolei, et al.
Publicado: (2019)

Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions
por: Schachne, Jonathan M, et al.
Publicado: (2021)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
por: Seong, Gyeol, et al.
Publicado: (2020)

Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers
por: Spencer, Elizabeth A, et al.
Publicado: (2020)

The safety of accelerated infusion versus standard rate infusion of low-molecular-weight iron dextran in patients with chronic kidney disease
por: Sinha, Smeeta, et al.
Publicado: (2009)

Successful Treatment of Tolosa-Hunt Syndrome after a Single Infusion of Infliximab
por: Halabi, Tarek, et al.
Publicado: (2018)

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma
por: Yamasaki-Morita, Makiko, et al.
Publicado: (2022)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit
por: Sandberg, Kelly C., et al.
Publicado: (2019)

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab
por: Scaldaferri, Franco, et al.
Publicado: (2017)

Radiopaque Resorbable Inferior Vena Cava Filter Infused with Gold Nanoparticles
por: Tian, Li, et al.
Publicado: (2017)

Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients’ Satisfaction and Cost Analysis. A Cohort Study in IBD Patients
por: Mazzuoli, S., et al.
Publicado: (2016)

Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
por: Lutfi, Forat, et al.
Publicado: (2020)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
por: Szymanska, Edyta, et al.
Publicado: (2021)

Development of anti-infliximab antibody is associated with reduced efficacy and infusion reaction in Behçet's disease with uveitis
por: Ishigatsubo, Y, et al.
Publicado: (2015)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice
por: Gaidos, Jill K J, et al.
Publicado: (2023)

Individualized treatment with infliximab therapy in children with Crohn’s disease support shorter time intervals between infusions
por: Sommar, M., et al.
Publicado: (2012)

Recurrent acute coronary syndrome after infliximab infusion in a patient with rheumatoid arthritis: Case report
por: Rebolledo Del Toro, Martin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ber7rhlq0bhclovg1n1v8upbd2